Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study (original) (raw)

2011, The Lancet Oncology

AI-generated Abstract

This cohort study investigates the cancer risk associated with EPCAM deletions in Lynch syndrome patients. Findings indicate that while EPCAM deletion carriers exhibit a high risk of developing colorectal cancer comparable to that seen in traditional MSH2 and MLH1 mutation carriers, their risk for endometrial cancer is significantly lower, possibly due to inadequate EPCAM expression in endometrial cancer progenitor cells. These results suggest the necessity for tailored cancer surveillance and risk management strategies for patients with EPCAM deletions.

Sign up for access to the world's latest research.

checkGet notified about relevant papers

checkSave papers to use in your research

checkJoin the discussion with peers

checkTrack your impact